drugset / Trial / NCT06772532

A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

NCT06772532

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.

Timeline

Start
2025-02-10
Primary completion
2025-05-29
Completion
2025-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Survodutide Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.